Catheter Precision, Inc. (VTAK) Stock Price & Analysis

Catheter Precision, Inc. (VTAK) rose 6.82% to USD 0.21 as of September 8, 2026 at 05:44 UTC, according to Nexqual real-time market data.

VTAK last closed at USD 0.2; the session ranged USD 0.19–0.21 on volume of 873,710 shares. Market capitalization is $757,988, with a 52-week range of USD 0.19–3.2 (ASE). Source: Nexqual, September 8, 2026 at 05:44 UTC.

Key Statistics (as of September 8, 2026 at 05:44 UTC)

Technical Analysis (VTAK)

Nexqual's technical model rates VTAK "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 05:44 UTC.

Analyst Ratings (VTAK)

Wall Street analysts rate VTAK "None", per Nexqual as of September 8, 2026 at 05:44 UTC.

Earnings (VTAK)

Recent Earnings History

Source: Nexqual, September 8, 2026 at 05:44 UTC.

Financials & Fundamentals (VTAK)

Source: Nexqual, September 8, 2026 at 05:44 UTC.

Financial Health Score (VTAK)

Nexqual rates Catheter Precision, Inc.'s overall financial health "Weak" across five dimensions, as of September 8, 2026 at 05:44 UTC.

Ownership (VTAK)

Source: Nexqual, September 8, 2026 at 05:44 UTC.

Leadership (VTAK)

Catheter Precision, Inc. is led by David A. Jenkins (age 67), CEO, Chief Commercial Officer & Executive Chairman, per Nexqual as of September 8, 2026 at 05:44 UTC.

From Catheter Precision, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)

Key Strengths & Strategy (as disclosed to the SEC)

• Our Vivo System is focused on the controlled delivery of these catheter technologies to enhance both the performance of ablation procedures and the ease and safety for the physicians who perform them.   6 Table of Contents   Our Products   VIVO ™ System   Our lead product, VIVO, is an FDA-cleared and CE marked product that utilizes non-invasive inputs to locate the origin of ventricular arrhythmias.
• As part of the PMA review, the FDA will typically inspect the manufacturer's facilities for compliance with Quality System Regulations, or QSR, requirements, which impose elaborate testing, control, documentation and other quality assurance procedures.
• In some instances, this study showed that VIVO has better predictability for arrhythmia origin than a physician's manual review of a 12 lead ECG.   While conducting the initial clinical study for FDA submission, we developed generation 2 in parallel with a goal to have this version complete and ready to submit upon 510(k) clearance of generation 1.
• If successful, this version will have expanded indications to include ischemic heart disease and improve usability by the hospital staff.  It would also contain more automaticity, potentially reducing our need for clinical support.   Resources Material to Our Business   Patents and Proprietary Technology   Patents   We have a number of patents covering our intellectual property, both in the U.S., as well in a number of international countries.

Partnerships

• For the U.S., our key patents include:     License and Other Agreements   PEACS, NV Software and Technology License Agreement   On May 1, 2016, we entered into a certain Software and Technology License Agreement with PEACS, NV, a Netherlands company, or the License Agreement, for the exclusive worldwide license of the underlying technology to the VIVO product, including intellectual property rights and patent applications pertaining thereto.
• Pursuant to the Royalty Agreement, we agreed to pay a royalty fee of 5% on net sales up to $1 million.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:44 UTC. This page is informational and not investment advice.